Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Retained Earnings (2021 - 2025)

Senti Biosciences has reported Retained Earnings over the past 5 years, most recently at -$358.6 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 20.69% year-over-year to -$358.6 million; the TTM value through Dec 2025 reached -$358.6 million, down 20.69%, while the annual FY2025 figure was -$358.6 million, 20.69% down from the prior year.
  • Retained Earnings for Q4 2025 was -$358.6 million at Senti Biosciences, down from -$344.1 million in the prior quarter.
  • Over five years, Retained Earnings peaked at -$1178.0 in Q1 2021 and troughed at -$358.6 million in Q4 2025.
  • A 5-year average of -$194.4 million and a median of -$218.2 million in 2023 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: plummeted 864587.1% in 2022 and later dropped 16.06% in 2025.
  • Year by year, Retained Earnings stood at -$115.1 million in 2021, then crashed by 50.55% to -$173.3 million in 2022, then tumbled by 41.01% to -$244.3 million in 2023, then decreased by 21.6% to -$297.1 million in 2024, then fell by 20.69% to -$358.6 million in 2025.
  • Business Quant data shows Retained Earnings for SNTI at -$358.6 million in Q4 2025, -$344.1 million in Q3 2025, and -$326.0 million in Q2 2025.